NPPB and heart failure: Despite the high predictive value of NT-proBNP, the GUIDE-IT study, a large randomized controlled trial evaluating NT-proBNP-guided therapy for heart failure with reduced ejection fraction, was terminated early due to futility, showing no outcome differences compared to the standard care and current evidence does not support NT-proBNP-guided therapy for chronic heart failure [9].